Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases

SUNNYVALE, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration (FDA) for the company's new drug application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection f...

Xcytrin in Medical Technology

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Program as Combination Agent with Standard Chemotherapies and Pivotal Lung Cancer Trial Scheduled to Begin Early Next Year - CHICAGO and SUNNYVALE, Calif. June 01, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced promisin...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product ca...

Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

...trin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating xcytrin as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, a...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

...trin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating xcytrin as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, a...

Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting

...erapy: Preliminary results of Stage 1 About xcytrin Pharmacyclics is developing xcytrin as an anti-cancer agent with a novel mechanism of ...maging detectability, provides the opportunity for xcytrin to be used in a broad range of cancers. About Ph...